Spruce Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Spruce Biosciences's estimated annual revenue is currently $5M per year.
- Spruce Biosciences's estimated revenue per employee is $90,182
- Spruce Biosciences's total funding is $108M.
- Spruce Biosciences's current valuation is $77.9M. (January 2022)
Employee Data
- Spruce Biosciences has 55 Employees.
- Spruce Biosciences grew their employee count by 6% last year.
Spruce Biosciences's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP, Pharmaceutical Development and Manufacturing | Reveal Email/Phone |
4 | VP, Development Operations | Reveal Email/Phone |
5 | VP, Clinical Development | Reveal Email/Phone |
6 | VP Clinical Operations | Reveal Email/Phone |
7 | President and Chief Financial Officer | Reveal Email/Phone |
8 | Senior Director, Finance | Reveal Email/Phone |
9 | Chief Regulator & Quality Officer | Reveal Email/Phone |
10 | Director Analytical Development | Reveal Email/Phone |
Spruce Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Spruce Biosciences?
Spruce Biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.
keywords:N/A$108M
Total Funding
55
Number of Employees
$5M
Revenue (est)
6%
Employee Growth %
$77.9M
Valuation
N/A
Accelerator
Spruce Biosciences News
Dr. Dias most recently served as chief medical officer at Spruce Biosciences Inc. Prior to that, he served as CMO at Indivior PLC.
Spruce Biosciences, Inc. (NASDAQ:SPRB Get Rating) has earned a consensus recommendation of Buy from the nine ratings firms that are...
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine...
SAN FRANCISCO--(BUSINESS WIRE)--Mar 22, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the fou ...
SAN FRANCISCO--(BUSINESS WIRE)--Mar 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, presented data from its Phase 1 and 2 programs of ti ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 58 | -32% | N/A |
#2 | $17.6M | 60 | 0% | N/A |
#3 | $20.8M | 77 | 10% | N/A |
#4 | $24.1M | 83 | 2% | N/A |
#5 | $10.8M | 90 | 14% | N/A |